Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,628 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Active, not recruiting Not applicable Interventional

A Randomized Parallel Clinical Trial of AIDANET, an Automated Insulin Delivery Algorithm, in Fully Closed-Loop Vs Hybrid Closed-Loop Mode In Adults With Type 1 Diabetes (AIDANET At Home)

NCT07039617
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AIDANET + FCL, AIDANET + HCL, AIDANET in FCL-HCL-mixed mode, Automated Insulin Delivery (AID) (usual care)
Device · Other
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Supplements and Aging Muscle

NCT01057082
View directory record Official record
Conditions
Sarcopenia
Interventions
Juven
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide and Radiation Therapy in Treating Patients With Gliomas

NCT00114140
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Temozolomide, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Newark, Delaware + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 30, 2026, 3:42 AM EDT
Terminated No phase listed Observational

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

NCT00900068
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
immunoenzyme technique, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 3 Interventional

ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD

NCT00557960
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Mixed salts of a single-entity amphetamine, Atomoxetine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 1 Interventional

Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

NCT01480050
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, 3'-deoxy-3'-[18F]fluorothymidine, pharmacological study, Mibefradil
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 30, 2026, 3:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Daily Protein Pacing Effects on HbA1c in Type 2 Diabetics

NCT05355090
View directory record Official record
Conditions
Type 2 Diabetes, HbA1c, Protein Intake
Interventions
PP
Dietary Supplement
Lead sponsor
Skidmore College
Other
Eligibility
30 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

NCT00253435
View directory record Official record
Conditions
Neuroblastoma
Interventions
Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 29 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rescuing the Microbiome Effectively With Different Doses of B. Infantis in Infants

NCT03476447
View directory record Official record
Conditions
Gut Microbiome
Interventions
B. infantis EVC001, Lactose
Other
Lead sponsor
Evolve BioSystems, Inc.
Industry
Eligibility
2 Months to 4 Months
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Not applicable Interventional

Precision Medicine Guided Treatment for Cancer Pain

NCT02664350
View directory record Official record
Conditions
Pain, CYP2D6 Polymorphism
Interventions
CYP2D6, Brief Pain Inventory-Short Form (BPI-SF), M.D. Anderson Symptom Inventory (MDASI), OPRM1
Genetic · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)

NCT01451151
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
2
States / cities
Los Angeles, California • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intergenerational Strengths-Based Program for American Indian Girls as They Transition to Adulthood

NCT03900312
View directory record Official record
Conditions
Sexual Activity, Sex, Alcohol Use, Pregnancy, Drug Use
Interventions
Asdzaan Be'eena' Program
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
8 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chinle, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a Dietary Supplement on Exercise Performance in Healthy Older Adults"

NCT01073332
View directory record Official record
Conditions
Excessive Physical Exercise, Unspecified
Interventions
Arginine antioxidant supplements, Placebo
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

NCT04998201
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-APOC3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Beverly Hills, California • Northridge, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

NCT00309699
View directory record Official record
Conditions
Bipolar Disorder, Mood Disorders
Interventions
Placebo, Quetiapine, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Cerritos, California • Garden Grove, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme

NCT00892177
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
bevacizumab, dasatinib, placebo
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
305
States / cities
Scottsdale, Arizona • La Jolla, California • Pismo Beach, California + 179 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 3 Interventional Results available

Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

NCT05157841
View directory record Official record
Conditions
Bunionectomy, Hallux Valgus
Interventions
Bupivacaine liposome injectable suspension 266 mg, Bupivacaine HCl, Bupivacaine liposome injectable suspension 133 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
North Little Rock, Arkansas • Pasadena, California • Dayton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 30, 2026, 3:42 AM EDT
Recruiting Not applicable Interventional

Tele-PROTECT Therapy: Effectiveness, Empowerment, and Implementation

NCT06039930
View directory record Official record
Conditions
Depression, Elder Abuse
Interventions
Tele PROTECT, Depression Education
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 30, 2026, 3:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

NCT00113919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Busulfan
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Lymphoma

NCT00002835
View directory record Official record
Conditions
Lymphoma
Interventions
Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa, Carmustine, Cisplatin (CDDP), Cyclophosphamide, Cytarabine (ARA-C), Etoposide (VP-16), Idarubicin, Ifosfamide, Leucovorin Calcium, Melphalan, Methotrexate, Methylprednisolone, mitoxantrone hydrochloride (DHAD), Vincristine Sulfate, Peripheral Blood Stem Cell Transplantation, Radiation Therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 59 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide in Treating Patients With Low-Grade Glioma

NCT00313729
View directory record Official record
Conditions
CNS Tumor, Adult
Interventions
temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Not applicable Interventional Results available

Reducing the Transition From Acute to Chronic Musculoskeletal Pain Among Older Adults

NCT04118595
View directory record Official record
Conditions
Acute Musculoskeletal Pain, Chronic Pain
Interventions
Educational Video, Telecare, Correspondence with Primary Care Provider
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 30, 2026, 3:42 AM EDT
Completed Not applicable Interventional Results available

Osia CPT Code Study

NCT04320407
View directory record Official record
Conditions
Conductive Hearing Loss, Mixed Hearing Loss
Interventions
Osia 2 System
Device
Lead sponsor
Cochlear
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • Tucson, Arizona • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 30, 2026, 3:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

NCT00577798
View directory record Official record
Conditions
Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
Interventions
contrast-enhanced magnetic resonance imaging
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 30, 2026, 3:42 AM EDT